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Abstract
The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique 
research platform and network to obtain substantial knowledge about several important risk and prognostic factors in major 
chronic diseases. A random sample of 45,000 participants between 45 and 74 years of age from the general population of 
Hamburg, Germany, are taking part in an extensive baseline assessment at one dedicated study center. Participants undergo 
13 validated and 5 novel examinations primarily targeting major organ system function and structures including extensive 
imaging examinations. The protocol includes validate self-reports via questionnaires regarding lifestyle and environmental 
conditions, dietary habits, physical condition and activity, sexual dysfunction, professional life, psychosocial context and 
burden, quality of life, digital media use, occupational, medical and family history as well as healthcare utilization. The 
assessment is completed by genomic and proteomic characterization. Beyond the identification of classical risk factors for 
major chronic diseases and survivorship, the core intention is to gather valid prevalence and incidence, and to develop com-
plex models predicting health outcomes based on a multitude of examination data, imaging, biomarker, psychosocial and 
behavioral assessments. Participants at risk for coronary artery disease, atrial fibrillation, heart failure, stroke and dementia 
are invited for a visit to conduct an additional MRI examination of either heart or brain. Endpoint assessment of the overall 
sample will be completed through repeated follow-up examinations and surveys as well as related individual routine data 
from involved health and pension insurances. The study is targeting the complex relationship between biologic and psy-
chosocial risk and resilience factors, chronic disease, health care use, survivorship and health as well as favorable and bad 
prognosis within a unique, large-scale long-term assessment with the perspective of further examinations after 6 years in a 
representative European metropolitan population.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1065 4-019-00577 -4) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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Introduction
Within the last decades, a change in the disease pattern has 
been observed. Today, the majority of the ageing popula-
tions in industrialized parts of the world will survive acute 
events and move into survivorship living with one or more 
of the following conditions, e.g., cardiovascular and neu-
rovascular disease, cancer, respiratory diseases, diabetes 
[1]. This change is mostly explained by better diagnostics 
leading to identification of disease at an earlier stage and 
to the development of more effective treatments of these 
diseases.
In addition to the change in disease patterns a change in 
diagnostic abilities and personalized treatment opportuni-
ties has occurred. The integration of imaging, molecular 
biology and clinical information holds promise to better 
detect at risk individuals and to personalize treatment.
Besides this new perspective of living for years at risk 
or in treatment for a chronic health condition, this may 
also influence physical, mental and sexual health, quality 
of life, general disability and society’s health expenses. In 
Germany, like in other affluent industrialized countries, 
the above mentioned chronic disease epidemic accounts 
for more than a third of the annual health expenditures, 
almost half of the total hospital payments [2]. It was esti-
mated in 2013, that 500,000 potentially productive life 
years were lost due to premature death by these conditions 
in the working-age population (29–59 years of age [3]).
Observational studies have changed practice of medi-
cine and lifestyle for millions of people [4], e.g., the 
Framingham Heart Study, which for the first time identi-
fied risk factors for cardiovascular events [4]. The condi-
tions for those who actually survived these diseases were 
only a minor part of the agenda. Thus, we established a 
prospective observational cohort study that can address the 
impact of information from biological samples, medical 
examinations and imaging, classic self-reported question-
naire data and their interplay on our understanding of com-
mon disease development. Issues of disease development, 
pathophysiological understanding, artificial intelligence 
and survivorship constitute the cornerstones of the Ham-
burg City Health Study.
Moreover, we establish a biobank including a wide vari-
ety of biomaterials enabling molecular analyses, that—in 
total, will lead to a better understanding of health, disease 
and survivorship.
Objectives
The Hamburg City Health Study has established a unique 
research platform with multiple risk assessment, numer-
ous outcomes and imaging examinations in all partici-
pants, a sophisticated biobank and interdisciplinary net-
work to address a wide range of questions about more 
than 30 major chronic diseases (see Box 1 and Fig. 1) and 
survivorship. 
Therefore, the primary aims of the HCHS are to inves-
tigate in detail:
• the causes for the development of functional health 
impairments and major chronic diseases,
• the prognostic factors for surviving chronic diseases 
and
• identification of factors supporting life in survivorship 
of major chronic diseases.
Study design and methods
Hamburg is the second largest city in Germany with 
1,830,584 million inhabitants (31.12.2017 [5] from all 
social classes living in 7 districts and 104 urban quarters. 
The city is mostly urban, but has also some rural areas and 
a large harbor contributing to the environmental exposures 
of the population. 839,389 persons are older than 45 years 
and in 2017 approximately 90,000 persons moved away. 
On an annual basis a sample census is carried out map-
ping social conditions of the German population includ-
ing a random sample of 1% of the whole population. As 
shown in Box 2 the Hamburg population in comparison to 
the German population is characterized by 4% more other 
nationalities, people are 7% more often single, 14% have 
a higher education and a higher income.
A total of 45,000 inhabitants, aged 45–74 years are to 
be included, identified by a random sample from the offi-
cial inhabitant data file divided into six age and gender 
strata. The HCHS is a joint interdisciplinary endeavor 
of physicians and scientists from the University Medical 
Center Hamburg-Eppendorf. Over 30 departments and 
institutes from the University Medical Center Hamburg-
Eppendorf work together in a unique cooperation at a sin-
gle study center.
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Pilot study, timeline and examinations
From May 08, 2015 until January, 31 2016 1800 volun-
teers in the age group 18–85 were recruited by a commer-
cial campaign in the leading newspaper from Hamburg 
and took part to validate the invitation process and train 
the study nurses in the examination procedures. Moreover, 
the manageability of the questionnaires was tested. This 
pilot study led to minor changes in these aspects. The first 
participant was enrolled on February 08, 2016 in the main 
Box 1  Overview of the main outcomes: the Hamburg City Health Study
Main outcome





Cancer such as prostate cancer and skin cancer
Chronic kidney diseases
Arterial hypertension, hypercholesteremia and valvular diseases such as bicuspide aortic valve disease
Migraine
Musculoskeletal diseases such as osteoporosis and bone metastasis
Ocular diseases such as glaucoma, macular degeneration, fundus hypertonicus, retinal vessel disease and neoplasm
Oral health including periodontal disease and caries, oropharyngeal cancer and human papillomavirus (HPV)-infection
Psychiatric and psychosomatic disorders such as mental disorder or late – last depression
Pulmonary diseases such as chronic obstructive lung disease (COPD) and asthma
Sexual dysfunction
Skin diseases such as psoriasis, chronic wounds and inflammation
Vascular diseases such as cerebrovascular disease, aortic aneurysm, thrombosis and peripheral arterial disease
Fig. 1  Summary of aims and uniqueness: the Hamburg City Health Study
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study and the last participant is expected to be enrolled on 
November 30, 2022. The end of the first personal Follow-
Up is planned 6 years later in 2028.
The participants are contacted by a letter to their home 
address containing the invitation and an information leaflet 
providing basic study information. Participants organize 
their own appointment at the epidemiological study center 
at the University Medical Center Hamburg-Eppendorf. 
The appointment is initiated by a study nurse explain-
ing the study rationale and participants are asked to sign 
informed consent including study participation, an extrac-
tion of a skin punch to create induced pluripotent stem 
cells and either none, one or all of the following options: 
external, virtual or internal autopsy in the event of death. 
In the end, participants also sign a consent accepting that 
both double de-identified and pseudo-anonymized data 
may be transferred to cooperation partners. Participants 
are also asked for consent to match their health insurance 
and pension insurance data with the HCHS dataset. During 
a 7-h examination participants undergo validated exami-
nations of different organ systems such as anthropomet-
ric measures, resting blood pressure measurements, ECG 
tracings as well as validated physical examinations. Novel 
parts include detailed cardiovascular, cognitive and oral 
health phenotyping, skin screening, pulmonary function 
test, muscle tests and optical coherence tomography (see 
Box 3 for an overview of all examinations). At the end 
of the visit, a letter is handed out containing results of 
all examinations and standardized recommendations to 
be followed by the participants. Following the discussion 
with the local ethical committee only clinically relevant 
results are provided to the participants. Before, during and 
after the baseline visit validated self-report questionnaires 
asking for life style and environmental conditions, dietary 
habits, quality of life, physical and sexual dysfunction, 
professional life, psychosocial context and burden, digital 
Box 2  Selected characteristics of the target population: Results from the sample census (microcensus), Hamburg*
*Data retrieved by the Mikrozensus 2016/2017 Statistisches Amt für Hamburg und Schleswig–Holstein. Absolut numbers in 1000 asked per-
sons. The results of a 1% sample were extrapolated to the current population. The total number is varying due to missing data
**Based on the International Standard Classification of Education (ISCED) which belongs to the UNESCO
Feature Category Hamburg Germany p Value
Overall Men Women Overall Male Female
N(%) N(%) N(%) N(%) N(%) N(%)
Age
45–54 274.4 (42.9) 139.6 (44.3) 134.9 (41.5) 13,220 (39.8) 6657 (40.5) 6563 (39.0) 0.2615
55–64 208.5 (32.6) 102.4 (32.5) 106.1 (32.7) 11,698 (35.2) 5798 (35.3) 5900 (35.1)
65–74 156.9 (24.5) 72.9 (23.2) 84.0 (25.8) 8335 (25.1) 3966 (24.2) 4369 (26.0)
Nationality
German 1528 (84.4) 735 (82.9) 793 (85.8) 73,112 (88.5) 35,929 (87.6) 37,183 (89.4) < 0.001
Other 282 (15.6) 151 (17.1) 131 (14.2) 9526 (11.5) 5103 (12.4) 4423 (10.6)
Marital status
Married 679 (37.9) 339 (38.7) 340 (37.1) 37,194 (45.0) 18,679 (45.5) 18,515 (44.5) < 0.001
Single 881 (49.1) 467 (53.2) 414 (45.1) 34,348 (41.6) 18,852 (45.9) 15,496 (37.2)
Divorced 134 (7.5) 53 (6.0) 81 (8.8) 5717 (6.9) 2415 (5.9) 3303 (7.9)
Widowed 99 (5.5) 18 (2.0) 82 (8.9) 5379 (6.5) 1087 (2.6) 4292 (10.3)
School education**
Upper secondary education 721 (51.6) 362 (53.5) 359 (49.9) 22,543 (34.6) 11,757 (36.7) 10,786 (32.6) < 0.001
Lower secondary education 675 (48.4) 315 (46.5) 360 (50.1) 42523 (65.4) 20271 (63.3) 22253 (67.4)
Income in €
500 < 899 75 (9.8) 25 (5.5) 50 (12.3) 10,256 (17.5) 3675 (11.9) 6581 (23.8) < 0.001
900 < 1299 126 (16.4) 49 (10.7) 76 (18.7) 11984 (20.5) 4662 (15.1) 7322 (26.5)
1300 < 1499 79 (10.3) 36 (7.9) 43 (10.6) 5834 (10.0) 2807 (9.1) 3027 (11.0)
1500 < 1699 87 (11.4) 42 (9.2) 45 (11.1) 5336 (9.1) 2818 (9.1) 2518 (9.1)
1700 < 1999 115 (15.0) 59 (12.9) 57 (14.0) 6538 (11.2) 3783 (12.2) 2755 (10.0)
2000 < 2599 69 (9.0) 95 (20.7) 73 (18.0) 8724 (14.9) 5654 (18.3) 3070 (11.1)
2600 < 3199 86 (11.2) 54 (11.8) 32 (7.9) 4146 (7.1) 2953 (9.5) 1193 (4.3)
3200 < 4499 76 (9.9) 55 (12.0) 20 (4.9) 3611 (6.2) 2788 (9.0) 822 (3.0)
≥ 4500 53 (6.9) 43 (9.4) 10 (2.5) 2170 (3.7) 1827 (5.9) 344 (1.2)
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media use, medical and family history, occupational his-
tory as well as health care utilization are filled out (see 
Box 4 for an overview of all questionnaires). 
Validated risk scores are used to identify individuals at 
risk for coronary artery disease, atrial fibrillation, heart fail-
ure, stroke and dementia. After the baseline investigation, 
these score-positive participants are invited to the imaging 
examination including an MRI—examination of the heart 
and the thoracic aorta and/or brain depending on the target 
disease [6]. In order to establish a general control group, 
1500 random participants are invited to an MRI as well. Par-
ticipants at risk for osteoporosis or suspected bicuspid aortic 
valve disease, prostate cancer, HPV-infection or dementia 
are recommended a further medical clarification.
Laboratory parameters and biobanking
A panel of basic laboratory analyses are performed on 
the day of the visit in the study center. The assessed 
markers include: sodium, potassium, HbA1c, prostate 
specific antigen (PSA), creatinine, high sensitivity meas-
ured CRP, glucose, thyroid stimulating hormone (TSH), 
triglycerides, total cholesterol, HDL-cholesterol, LDL/
HDL ratio, and N-terminal pro B-type natriuretic peptide 
(NTproBNP). Furthermore, a complete blood count is per-
formed. Biomaterials used for biobanking include serum, 
plasma (EDTA, citrate), genomic deoxyribonucleic acid 
(DNA), ribonucleic acid (RNA) from whole blood and 
peripheral blood mononuclear cells (PBMCs), blood cells 
Box 3  Overview of all components of the baseline examination high lightening novel and established clinical practice: the Hamburg City Health 
Study
Components of the baseline examination Variables
Novelty
2D and 3D transthoracic echocardiography Complete screening of aortic-, mitral- and tricuspid-valve. 4D-echocardiography of every partici-
pant of the whole left and right heart. Measurement of ventricular and atrial strain.
Lung function Performance of a broad/comprehensive screening by bodyplethysmography.
Ophthalmological examination Assessment of the objective refraction and subjective visual acuity, imaging of the macular and 
papillary retinal layers including intravasal flow visualization using swept source optical coher-
ence tomography.
Oral examination Scaling of periodontitis severity according to the CDC-AAP criteria and whole mouth examination 
with assessment of caries (DMFT index) and tooth status.
Ultrasound of the abdominal aorta Evaluation of the infrarenal abdominal aorta by using the b-mode and continuous-wave-Doppler-
mode ultrasound to measure the diameter at the maximum, the outer-to-outer-method is used. 
Maximum flow-velocity is measured in the infrarenal aorta.
Ultrasounds of the peripheral arteries B-mode and continuous-wave-Doppler-mode is used to evaluate flow-velocity and plaque burden of 
the common femoral, superficial femoral and popliteal arteries.
Established clinical practice
2D and 3D transthoracic echocardiography Volumes and function of all four heart chambers by 2D and 3D echocardiography; left ventricular 
diastolic function; left ventricular mass.
Ankle-brachial index (ABI) [7, 8] Manually measurement (Doppler ultrasound) of systolic blood pressures at the posterior tibial, the 
anterior tibial, and the brachial arteries.
Anthropometry Assessment of Weight, height and measurement of waist and hip circumferences.
Blood pressure measurement Measurement after 5 min rest and 3 determination sitting and lying.
Cognitive function Screening for impairment of cognitive function: Mini-Mental State Exam (MMSE), Clock Drawing 
Test (CDT); test of cognitive function: verbal fluency, semantic and vocabulary memory, visual 
attention and task switching, response inhibition, visuospatial abilities, cognitive processing 
speed, executive function.
Electrocardiography Assessment with a standard digital 12-lead ECG and 2-min rhythm strip.
Lung function Assessment of spirometry.
Muscle status and coordination Assessment of hand-grip strength, Timed-up and go Test, Chair–Rising Test, Tandem Test.
Oral examination Assessment of tooth status (DMFT index), pocket probing depths (periodontitis), bleeding on prob-
ing (gingivitis), dental plaque, condition of hard and soft tissues, assessment of craniomandibular 
dysfunctions, saliva and sulcus fluid sampling, oral hygiene behavior and oral health literacy.
Physical activity [9–11] Objective measure of physical activity with Actigraph.
Standardized neurological examination Assessment of the National Institutes of Health Stroke Scale.
Ultrasound of the carotid artery B-mode and continuous-wave-Doppler-mode is used to evaluate flow-velocity and plaque burden of 
the carotid artery.
Ultrasound of the peripheral venous system The b-mode is used for venous compression ultrasound at the femoral and popliteal vene.
174 A. Jagodzinski et al.
1 3
Box 4  Overview of all components of the self-reported questionnaires: the Hamburg City Health Study
Component of questionnaire
Overview of dimensions and scales of the baseline and follow-up self-reported questionnaire
Adverse childhood experiences Adverse childhood experiences questionnaire (ACE) [12, 13]
Alcohol use Alcohol use disorders identification test (Audit-C) [14, 15]
Anxiety Generalized anxiety disorder screener (GAD-7) [16]
Chronotype (single items) Munich chronotype questionnaire (MCTQ) [17, 18]
Daytime sleepiness Epsworth sleepiness skala (ESS) [19]
Depression severity Patient health questionnaire (PHQ-9 D) [20–22]
Dermatology quality of life index Dermatology life quality index (DLQI) [23]
Family history of disease Physical & psychological diseases of parents
General practitioners (GP) guided care Use of general practitioner
Health beliefs Scale of the German health interview and examination survey for adults 
(DEGS-39) [24, 25]
General health perception Scale of the German health interview and examination survey for adults 
(DEGS-29) [24, 25]
Health economics Costs, EQ-5D-5L, ICER
Informal care
Lifestyle medicine European Prospective Investigation into Cancer and Nutrition (EPIC): 
Food Frequency [26] and Physical activity [27]
Living—environment—work General housing data, technical data, quality of living, housing and 
work
Medical history Allergies, gynaecology, skin diseases, cardiovascular diseases, cancer, 
ENT diseases, lung diseases, nephrology, neurology, orthopaedics, 
other diseases, dental and oral diseases
Medication-related beliefs Beliefs about Medicines Questionnaire (BMQ Short form) [28, 29]
Migraine questionnaire The rostock headache questionnaire (RoKoKo) [30]
Occupational exposure to fume, gases, organic or anorganic dust Exposure assessment, specifically adapted for HCHS, based on 
questionnaire of the European community respiratory health survey 
(ECRHS), occupational module
Optimism, pessimism SWOP
Oral health Oral health literacy, oral hygiene, oral hygiene behaviour, oral health 
care utilization, fluoride prophylaxis, nutrition, dental service utiliza-
tion [31–33]
Patient satisfaction Zufriedenheit in der ambulanten Versorgung [Satisfaction in outpatient 
care] (ZAPA) [34]
Quality of life European Quality of Life (EQ-5D-5L) [35], [36]
Short-Form Health Survey (SF-8) [37, 38]
Resilience RES-6
Risk factors and medical history National cohort study (NAKO) [39]
Sexual dysfunctions DSM—5 criteria
Shift and night work career history, jobs with shift and night work [40, 41]
Social support F-SozU-K14
Sociodemographic characteristics i.e. Gender, age, nationality, mother language, religion
Somatic symptom Patient Health Questionnaire (PHQ-15) PHQ-15 [42, 43]
Utilization of medical services Scales of the German Health Interview and Examination Survey for 
Adults (DEGS-9, DEGS-10, ÖKO-DEGS-15) [24]
Significant life events Social reactivity reaction scale (SRRS)
Smoking behavior Fagerström questionnaire, smoking anamnesis
Overview of dimensions and scales of the MRI self-reported questionnaire
Anxiety Generalized anxiety disorder (GAD-2) [44]
Daily life Social interaction, cognitive deficits, own psychological diseases & in 
the family
Depression Patient health questionnaire (PHQ-9) [20, 21]
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(erythrocytes, PBMCs), urine, saliva as well as tooth fluid 
and tonsils swabs. Additionally, from a random subset 
of study participants, skin stanza are collected of which 
fibroblasts are separated. These fibroblasts will be used 
for the generation of human induced pluripotent stem cells 
(hiPSCs) (for an overview of all biomaterials collected 
and planned measurements see Box 5). Subsequently, the 
biomaterial will be examined by state-of-the-art and inno-
vative, high throughput approaches including analyses on 
the different OMICS levels such as genomics, transcrip-
tomics, proteomics and lipidomics profiling. One part of 
the biobank is used for research projects within the first 
6 years, the second part is stored for projects performed 
during the studies follow up and in the future.
Follow‑up
Following the date of baseline examination, all participants 
will be contacted by mail containing a questionnaire which 
specifically ask participants to report any major medical 
event, medication, nutrition and lifestyle changes, physical 
and mental health, sexual dysfunction and overall quality of 
life as well as health care use. Participants are also asked to 
provide discharge letters or any kind of further information 
Box 4  (continued)
Component of questionnaire
Emotional regulation Questions from the response styles questionnaire (RSQ-D) [45, 46]
Emotional well-being Current personal condition
Health advice Scale of the German health interview and examination survey for adults 
(DEGS-11) [24]
Health behaviour measures Scale of the German health interview and examination survey for adults 
(DEGS-20) [24]
Health care satisfaction Zufriedenheit in der ambulanten Versorgung/[Satisfaction in outpatient 
care] (ZAPA) [34, 46]
Health literacy Patient Activation Measure (PAM-13)
Health risks perception
Media consumption Patterns of media consumption
Medication-related beliefs Beliefs about medicines questionnaire (BMQ Short form) [28, 29]
Personality Eysenck personality questionnaire (EPG-RK) [47]
Quality of life Short-Form Health Survey (SF-8) [37, 38]
Self-efficacy Skala zur Allgemeinen Selbstwirksamkeits-erwartung [Self-efficacy 
scale] (SWE)
Significant life events Social readjustment rating scale (SRRS)
Somatic Symptoms Somatic symptom disorder-B criteria scale SSD-12) [48]
Somatic Symptom Scale (SSS-8) [43]
Box 5  Overview of all collected biospecimen and purposes: the Hamburg City Health Study
Biospecimen Novelty
Serum Measurement of routine biomarkers as well as innovative markers such as non-coding RNA, proteomics, metabolomics and 
viruses
EDTA plasma Measurement of routine biomarkers as well as innovative markers such as ncRNA, proteomics, metabolomics and viruses
Citrat plasma Measurement of routine biomarkers and innovative markers of coagulation cascade
Genomic DNA Measurement genomic and epigenomic markers
Whole blood RNA Measurement of gene expression and expression of non-coding RNA
Erythrocytes Measurement of innovative biomarkers and protein activity
PBMC Generation of iPS cells, and cell culture experiments, Gene expression and measurement of circulating tumorcells (CTC)
Urine Measurement of innovative markers
Saliva Measurement of innovative biomarkers and oral microbiome
Tooth fluid Measurement of oral microbiome
Tonsils swab Measurement of oral microbiome and viruses
Skin Tissue Generation of iPS cells
176 A. Jagodzinski et al.
1 3
on their health such as diagnostic findings or images. This 
contact takes place on an annual basis for 5 years. An end-
point-committee will review all collected information for 
special endpoints. After 6 years all participants are invited 
to undergo the same examination and procedures as in the 
baseline visit. On a continuous basis the study center is in 
contact with public authorities and the cancer register about 
vital status, cause of death and cancer incidence and in con-
tact with involved health and pension insurances to match 
with related individual routine data.
Statistical analysis plan
The integrity of the collected data in the databases are con-
trolled by detailed, predefined quality control algorithms 
according to standardized operation procedures (SOP) con-
cerning detection of outliers, logically implausibility, or 
detect mistaken identity. Only quality controlled data will 
be used for statistical analyses.
In the analyses of baseline data methods for cross-sec-
tional analyses will be applied. Univariate statistics for cat-
egorical variables will be presented as counts and propor-
tions, and numeric variables will be presented as means, 
percentiles and standard deviations. Associations between 
baseline characteristics will be estimated by means general-
ized linear regression models.
For the full cohort as well as for sub-cohorts, time-to-
event methods constitute the major approach for identify-
ing and assessing risk factors for mortality and incidence 
or progression of diseases. Thus, when studying rates of a 
single event type, e.g., overall mortality, regression models 
for censored data will be used to simultaneously investi-
gate the effects of risk factors of interest while adjusting for 
potential confounders.
In all analyses, effect estimates will be presented both, in 
relative terms as prevalence or risk ratios, and in absolute 
terms as means, rates or risks, the latter to assess public 
health implications. All effect estimates and statistical sum-
maries will be presented with 95% confidence intervals, and, 
when appropriate, adjusted for multiple testing. For disease-
specific mortality or endpoints other than death, competing 
risks will be accounted for. For repeated measurements in 
the second examination, regression models for longitudinal 
data will be employed. In all analyses observations may be 
correlated either in time (repeated measures) or between 
subjects (e.g. relatives). Appropriate statistical methods 
will be used to account for correlated observations, e.g. by 
means of mixed effect models, or in marginal models by 
means of generalized estimating equations (GEE). Special 
attention will be paid to potentially informative drop-out or 
failure to obtain further measurements due to the occurrence 
of a specific event. These issues will be addressed by joint 
models for longitudinal and time-to-event data. In cases of a 
substantial amount of missingness in dependent or independ-
ent variables, multiple imputation will be incorporated in 
the analysis, as a supplement to the complete case analysis. 
To ensure transparency and reproducibility of results, all 
statistical methods and codes will be described and stored 
centrally as a supplement to study protocols. This material 
will be available to other researchers upon request.
Ethical concerns
During the study conception, the local ethics committee of 
the Landesärztekammer Hamburg (State of Hamburg Cham-
ber of Medical Practitioners, PV5131) was consulted and its 
approval for the study protocol as well as the approval by 
the Data Protection Commissioner of the University Medi-
cal Center of the University Hamburg-Eppendorf and the 
Data Protection Commissioner of the Free and Hanseatic 
City of Hamburg were obtained. The study has been regis-
tered at ClinicalTrial.gov (NCT03934957). The procedures 
set out in this study, pertaining to the conduct, evaluation, 
and documentation, are designed to ensure that all persons 
involved in the study abide by Good Clinical Practice (GCP), 
Good Epidemiological Practice (GEP) and the ethical prin-
ciples described in the current revision of the Declaration 
of Helsinki. The study will be carried out in keeping with 
local legal and regulatory requirements. The requirements 
of the GCP and GEP regulation will be adhered to. In order 
to be admitted to HCHS, all participants are to consent to 
participate only after the nature and scope of the study have 
been explained to and understood by them. Written informed 
consent is obtained from all participants. The examinations 
were chosen because of non-invasive nature of acquisition 
and standardized testing to assess intermediate phenotypes 
of the different diseases. Well-characterized intermediate 
phenotypes are of great value for screening, patient moni-
toring and in the context with clinical trials. At the end of the 
baseline- and MRI- examinations, all participants receive a 
standardized report of all relevant clinical results with a pos-
sible recommendation of referral to the general practitioner. 
Recommendations for all findings were defined before study 
start and standardized. Findings, which need clinical refer-
ral immediately, are defined as well and reported directly to 
the participants. If required, participants are also accompa-
nied to the emergency department of the University Medical 
Center Hamburg-Eppendorf by a member of the study staff.
Data protection concerns
During the study conception, the Data Protection Commis-
sioner of the University Medical Center Hamburg-Eppen-
dorf and the Data Protection Commissioner of the Free 
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and Hanseatic City of Hamburg were consulted and their 
approval for the study protocol was obtained (D4/17.06-22). 
The requirements of the Federal Data Protection Law (Bun-
desdatenschutzgesetz), the European General Data Protec-
tion Regulation and the law of Hamburg Hospitals (Ham-
burger Krankenhausgesetz) will be adhered to. Subjects will 
be identified solely by means of an individual identifica-
tion code and data are only collected, stored and analysed 
pseudo-anonymized. To enhance data confidentiality, data, 
lab samples and genetic results have different identification 
numbers. The identification numbers will change between 
data collection, storage and disclosure. To avoid mistakes 
in assigning the right identification number, the pseudo-
anonymization is conducted electronically. All data will be 
stored at the study centre and all analytical activity will take 
place at dedicated workstations situated at the study centre. 
Extensive surveillance and login of all activity will be car-
ried out.
Strengths and limitations
Most importantly, the HCHS is a prospective population-
based cohort study, which enables cause and effect analyses 
investigating major risk factors for a number of symptoms 
and chronic diseases. In addition, the extensive annual 
follow-up also contributes to the advantages of the HCHS. 
Further, the high number of examinations including a range 
of novel approaches in different disciplines contributes 
to the fact that data from the HCHS may unravel hitherto 
unknown causal associations. In line with this consideration, 
the extensive analyses planned with the use of biological 
samples giving basic genomic information in combination 
with phenotypic data will provide a rich data source for 
advanced analyses. The high number of participants secures 
that even relatively rare outcomes may be investigated. Fur-
thermore, it is the ambition to link the data from the HCHS 
to socioeconomic information and individual records indi-
cating information about diseases, prescribed medications, 
in- and outpatient health care use as well as sick leave etc. 
The cohort recruitment allows that prevalent cases of most 
chronic diseases will be enrolled and thereby opens up for 
early cross-sectional analyses investigating associations 
leading to hypothesis driven studies when the first 10.000 
participants are included and when the cohort is complete. 
In line with this consideration, one may also point to the 
possibility of describing the distribution of diseases asso-
ciated with patterns of several factors, i.e. socioeconomic 
status in diabetes patients, nutrition and lifestyle factors in 
dementia or the association between skin disorder and den-
tal status. The design also offers an opportunity to conduct 
more complicated disease trajectory analyses using patterns 
of symptoms and diseases as both causes and effects. It is 
also of vital importance that this study offers an opportunity 
to investigate determinants of survival and survivorship in 
accordance with the aims of the study.
Even prospective cohort studies will have limitations due 
to selection bias in participation and recall bias. This study 
mostly relies on the recall of participants as the method of 
achieving information about central outcomes during the 
6 years of follow-up. This limitation will be addressed by 
obtaining data from health insurance and pension funds. 
Compared to cohort studies investigating risk factors of 
diseases characterized by high incidence rates the waiting 
time for incident outcomes in diseases having low incidence 
rates is longer. Conducting a multidimensional study also 
reduces the number of participants with complete data, and 
as funding is limited, this problem represents a true limita-
tion of the data set, which in the end will be less than a 100% 
complete. From a more technical point of view, some data 
may not be collected due to participants wish, lack of staff 
or technical malfunction of equipment. To address this limi-
tation, standardized quality controls are performed weekly 
to detect missing data in order to ensure that no systematic 
processes are in function. Birthday, Christmas cards and 
annual newsletters will remind the participant to inform the 
study centre in the event of a medical endpoint. A number 
of standardized operating procedures for the recruitment, 
collecting and storage of data, quality control and analyses 
will be established. To avoid endpoint misclassification, an 
interdisciplinary endpoint committee will render an expert 
opinion on the basis of discharge letters or further informa-
tion. The integrity of the collected data in the databases is 
controlled by detailed, predefined quality control algorithms 
according to standardized operating procedures in batches 
concerning detection of outliers, logically implausibility, or 
detect mistaken identity. Only quality-controlled data are 
used for statistical analyses.
Conclusion
In future, data from HCHS will strongly contribute to our 
knowledge about risk factors for and prognostic factors in 
major chronic diseases, survival and survivorship. It will be 
a unique source due to the combination of self-reported data, 
detailed imaging data, a vast number of biological informa-
tion and unbiased administrative data established independ-
ent of the hypothesis of the study. It is the aspiration that the 
inclusion of novel aspects in all exposure assessment meth-
ods concurrently with well-established, traditional epide-
miological tools across all exposures and outcome will help 
in achieving information of such quality so that it can feed 
directly into public health policy with regard to prevention 
and survivorship related aspects. In line with this aspiration, 
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the use of the data in real-life clinic is also one of the main 
intention in this study.
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